Prognostic factors of lung cancer in lymphoma survivors (the  LuCiLyS study)

Fiorelli, Alfonso; D’Andrilli, Antonio; Carlucci, Annalisa; Vicidomini, Giovanni; Loizzi, Domenico; Ardò, Nicoletta Pia; Marasco, Rita; Ventura, Luigi; Ampollini, Luca; Carbognani, Paolo; Bocchialini, Giovanni; Lococo, Filippo; Paci, Massimiliano; Stefano, Teresa Severina Di; Ardissone, Francesco; Gagliasso, Matteo; Mendogni, Paolo; Rosso, Lorenzo; Mazzucco, A.; Vanni, Camilla; Marinucci, Beatrice Trabalza; Potenza, Rossella; Matricardi, Alberto; Ragusa, Mark; Tassi, Valentina; Anile, Marco; Poggi, Camilla; Serra, Nicola; Sica, Antonello; Nosotti, Mario; Sollitto, Francesco; Venuta, Federico; Rendina, Erino Angelo; Puma, Francesco; Santini, Mario

doi:10.21037/tlcr.2019.12.28

Cited by 14 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone marrow examination should be considered. According to Senff et al, legs as a presentation site influence the prognosis, with an overall survival of 41% at 5 years [71-72]; coexistence with DLBCL also worsens the prognosis of PCFCL (23,24). Transformation of PCFCL into DLBCL is not very rare and together with transformations into another type of high-grade lymphoma represents negative prognostic factors.…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

“…Solitary lesions require radiation therapy or complete surgical excisions with curative intent. Several authors recommend the use of LDRT (4 Gy) for their better outcome and reduced toxicity in particular in all indolent forms (24). Intralesional (e.g., corticosteroids or rituximab) or topical therapies (e.g., corticosteroids, nitrogen mustard, imiquimod, cryotherapy) may also be considered.…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

“…Cutaneous recurrences are frequently observed (30-46.5%), usually confined to the skin. Followup intervals are appropriate every 6 months and consist of a complete cutaneous and nodal clinical examination (23,24).…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

See 2 more Smart Citations

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis. They include ∼25% of all cutaneous lymphomas and are classified in three major subgroups (World Health Organization (WHO) 2017): primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center cell lymphoma (PCFCL), and diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). This classification also includes some less common entities such as intravascular large B-cell lymphoma. Recently, WHO-EORTC added Epstein-Barr virus positive (EBV+) mucocutaneous ulcer, as a new provisional distinct entity, to cutaneous B-cell lymphomas. PCBCLs are classically characterized by patches, plaques, or nodules showing great variability for color, shape, and location. Diagnosis requires histological examination with immunohistochemical staining. In general, therapeutic options depend on the exact histological and immunohistochemical classification, disease presentation, and risk assessment. PCMZL and PCFCL are considered indolent lymphomas with a good prognosis and are associated with 5-year disease-specific survival ≥ 95%. In contrast, PCDLBCL, LT is considered an aggressive lymphoma with a survival rate in 5 years of lower than 60%. Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments as compared to patients with generalized lesions or refractory disease or extracutaneous involvement. Therapeutic choice includes observation, local, or systemic therapy based on histology and disease extension. Patient management is multidisciplinary, including dermatologists, pathologists, hemato-oncologists, and radiation oncologists.

show abstract

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Myocardial, liver, and kidney injuries and secondary bacterial infection may also occur 25 . The presence of comorbidities (cardiovascular disease, hypertension, diabetes, chronic lung disease, renal failure, cerebrovascular disease, or malignancy) are the major risk factors for the development of the acute respiratory distress syndrome (ARDS) and the need for intensive care in 20% to 30% of cases, with a mortality rate around 10%, that, however, may reach 50% in adult aged more than 60 in some report 26 . The estimated symptomatic case‐fatality risk among cases observed in Wuhan was 1.4%, but elder patients (>59 years) had 5.1 times more likely to die than those 30 to 59 year old 27 .…”

Section: Clinical Presentation and Course Of Covid‐19mentioning

confidence: 99%

The impact of the SARS‐CoV‐2 infection, with special reference to the hematological setting

Sica

Casale

Rossi

et al. 2020

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a disease known from a few months, caused by a recently arisen virus and, consequently, it is little known. The disease has a benign course in most infected subjects (children and young adults), is often symptomatic in adults over the age of 50 and often serious and life threatening in people with comorbidities and the elderly. The few data published on coronavirus disease-2019 (COVID-19) in the blood-oncology field report a serious clinical presentation, a serious course of the disease, and a high mortality rate, as has also been reported for other cancer contexts. The current strategy for treating patients with SARS-CoV-2 includes antivirals that are effective against other viral infections and drugs that can moderate the cytokine storm. There is no specific vaccine and consequently all possible precautions must be taken to prevent SARS-CoV-2 infection in the areas of oncology, oncohematology, and bone marrow transplantation. In this reviewer's article, we report the information currently available on SARS-CoV-2 infection to help young doctors and hematologists to successfully manage patients with COVID-19.

show abstract

“…The subcutaneous spinal cord stimulation (SCS) is among the main innovative techniques to control the otherwise intractable chronic pain. SCS uses low voltage current that reaches the spinal cord through the application of epidural leads that stimulate nerve fibers blocking or weakening the transmission of pain (17)(18)(19)(20)(21). The subcutaneous SCS induces a tingling sensation in the patient that overlaps the area where the pain is felt.…”

mentioning

confidence: 99%